P
Psilera
Creating new drugs using a proprietary in-house drug discovery engine
About Psilera
Psilera is a biotechnology research company founded in 2019, with offices in New Jersey and Florida. The company is led by scientists and co-founded by women, focusing on developing next-generation medicines. Psilera specializes in creating and developing serotonergic compounds, which are chemicals that affect serotonin levels in the brain. These compounds have the potential to treat long-term cognitive diseases and improve the quality of life for patients.
The company operates in the pharmaceutical and biotechnology market, targeting clients such as medical researchers, pharmaceutical companies, and healthcare providers. Psilera's business model revolves around research and development (R&D) of novel compounds, securing patents, and collaborating with academic institutions. They have already filed 13 patents, with two issued, covering over 1 million unique compounds. This intellectual property can be licensed to pharmaceutical companies or used to develop new drugs, generating revenue.
Psilera's approach is rooted in the potential of natural medicines, including psychedelics, to address neurological diseases. They collaborate with scientific experts, such as Katie DeMarsh from the Medical College of Wisconsin, to advance their research. The company aims to unlock the power of these next-generation medicines to change how scientists and doctors view and treat the human mind.
In summary, Psilera is a pioneering biotech firm focused on developing innovative serotonergic compounds to treat cognitive diseases, leveraging a strong patent portfolio and scientific collaborations to drive its business.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Tampa, United States
- Employees
- 14
- Open positions
- None listed
- Dealroom signal
- 71.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, Woman Founder, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | May 2026 | $8.8M | $35M | Undisclosed | ↗ |
| GRANT✓Other financing | Oct 2025 | $2M | — | National Institutes of Health | ↗ |
Growth signals
Latest recorded traffic for Psilera is 2.1K monthly website visits, up 133.3% over the last three months. Psilera's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
Iter Investments- REReceptor
JLS Fund
What If Ventures
Baird Inc
University of South Florida
National Institutes of Health
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Psilera on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Psilera’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.